Key Highlights

  • 9.4 million USD is the net loss Oncolytics Biotech Inc. (NASDAQ:ONCY) reported for the second quarter of 2026, against USD 5.3 million a year earlier, a calculated increase of about 77% ahead of the November 16, 2026 report.
  • 4.1 million USD was the cash and equivalents balance on June 30, 2026, down from USD 5.2 million at year-end 2025, a calculated decline of about 21%, while the company states that additional financing is required.
  • 14.4 million USD in net proceeds came from at-the-market offerings during the first half of 2026, funding a six-month net loss of USD 18.7 million, compared with USD 10.0 million in the prior-year period.
  • 2 Fast Track designations were received in 2026 for pelareorep in combination use, covering metastatic colorectal cancer and squamous cell carcinoma of the anal canal, the two programs management is prioritizing.

What Investors Expect From Oncolytics Biotech Inc. (NASDAQ:ONCY) on November 16, 2026

Oncolytics Biotech Inc. (NASDAQ:ONCY), a clinical-stage company developing the intravenously delivered oncolytic virus pelareorep, is scheduled to report its third quarter 2026 results on Monday, November 16, 2026. The company generates no product revenue, so investors will watch spending, cash and clinical timelines. The comparison point is the second quarter of 2026, when the net loss was USD 9.4 million against USD 5.3 million in the second quarter of 2025, and the six-month net loss rose USD 8.7 million, a calculated 87%, to USD 18.7 million. The company has not issued numeric financial guidance.

The Rationale: Last Reported Quarter and Management Outlook for Oncolytics Biotech Inc. (NASDAQ:ONCY)

Research and development expense was USD 4.3 million in the second quarter of 2026 versus USD 1.9 million a year earlier, a calculated increase of about 126%, driven by clinical trial start-up activity and higher personnel costs. General and administrative expense rose to USD 5.1 million from USD 2.7 million, a calculated increase of about 89%, reflecting higher investor relations, legal and stock-based compensation costs. Management is focused on second-line metastatic colorectal and anal carcinoma programs, Manufacturing readiness and partnerships. The company completed its domestication to Nevada and received a new U.S. Patent covering manufacturing processes. Ongoing and planned registration-enabling studies cover metastatic colorectal, anal and pancreatic cancers.

Valuation, Liquidity and Risks for Oncolytics Biotech Inc. (NASDAQ:ONCY)

Liquidity is the central issue. Cash and equivalents of USD 4.1 million at June 30, 2026, a USD 1.1 million calculated drop since December 31, 2025, compare with a second quarter net loss of USD 9.4 million, which on a rough calculated basis equals less than half a quarter of that loss rate. The company states that its cash does not cover at least twelve months of planned operations and that it expects to keep using at-the-market programs and pursue collaborations. Risks include Equity dilution, clinical and regulatory uncertainty, dependence on a single therapy and manufacturing scale-up.

Where Things Stand

Oncolytics Biotech Inc. (NASDAQ:ONCY) approaches the November 16, 2026 report with its clinical profile improving and its Balance Sheet under pressure. Two Fast Track designations in 2026, a Nevada domestication and a new manufacturing patent mark progress on the regulatory and corporate side. Against that, the second quarter net loss of USD 9.4 million was 77% larger than a year earlier on a calculated basis, and cash of USD 4.1 million sat well below the USD 14.4 million raised through at-the-market offerings in the first half. The next report should clarify how far recent funding extends the runway and how management sequences its colorectal, anal and pancreatic programs.